Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase inhibitors (TKIs) are being actively developed for MET-driven NSCLC, the mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seulki, Kim, Tae Min, Kim, Dong-Wan, Kim, Soyeon, Kim, Miso, Ahn, Yong-Oon, Keam, Bhumsuk, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639226/
https://www.ncbi.nlm.nih.gov/pubmed/30309221
http://dx.doi.org/10.4143/crt.2018.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639226/
https://www.ncbi.nlm.nih.gov/pubmed/30309221
http://dx.doi.org/10.4143/crt.2018.052

Ejemplares similares